Osteoprotegerin - SnowBrand

Drug Profile

Osteoprotegerin - SnowBrand

Alternative Names: OCIF - SnowBrand; OPG - SnowBrand; Osteoclastogenesis Inhibiting Factor - SnowBrand

Latest Information Update: 20 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SnowBrand Pharmaceuticals
  • Class
  • Mechanism of Action Bone resorption factor inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone disorders; Postmenopausal osteoporosis

Most Recent Events

  • 10 Nov 1998 Preclinical development for Bone disorders in USA (Unknown route)
  • 10 Nov 1998 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top